Company: KROS
Filing Date: 2025-11-05
Form Type: 10-Q
Source: 0001664710-25-000089
Chunk: 280

Company: Keros Therapeutics, Inc.
Filing Date: 2025-11-05
Form: 10-Q
Item: Item 8
Chunk 280
---
 calendar year, or a lesser number of shares as may be determined by the Board. On January 1, 2025, the Company increased the number of shares available for future grant under the 2020 Plan by 1,622,188 shares. The awards granted under the 2020 Plan typically vest over a two- to four-year period and have a 10-year contractual term. As of September 30, 2025, there was an aggregate of 4,114,663 shares of common stock issuable upon the exercise of outstanding options and 721,700 shares of common stock issuable upon the vesting of the outstanding RSU awards under the 2020 Plan. Additionally, there were an aggregate of 2,554,450 shares reserved for future issuance under the 2020 Plan, including shares forfeited from the 2017 Plan.Restricted Stock UnitsA summary of RSU award activity during the nine months ended September 30, 2025 is as follows (in thousands except share and per share data):Number of UnitsWeighted Average Grant-Date Fair ValueOutstanding RSU awards as of December 31, 2024— $— Granted1,121,175 11.56 Vested— — Forfeited(399,475)10.56 Outstanding RSU awards as of September 30, 2025721,700 $12.11 The summary of RSU award activity includes performance-based awards granted during the nine months ended September 30, 2025. As of September 30, 2025, there has been no expense recognized for the performance-based awards. As of September 30, 2025, there was approximately $7.2 million of unrecognized stock-based compensation expense related to RSU awards that is expected to vest, including $1.4 million of unrecognized stock-based compensation expense related to performance-based awards for which the performance criteria is currently not deemed probable. These costs are expected to be recognized over a weighted-average remaining vesting period of approximately 1.79 years. Stock OptionsA summary of option activity during the nine months ended September 30, 2025 is as follows (in thousands except share and per share data):

13

NUMBER OF OPTIONSWEIGHTED-AVERAGE EXERCISE PRICEOutstanding as of December 31, 20245,384,760 $42.19 Granted84,000 14.82 Exercised(65,653)0